MX2009010660A - Derivados de purina substituidos-2,6,9 que tienen propiedades anti-proliferativas. - Google Patents

Derivados de purina substituidos-2,6,9 que tienen propiedades anti-proliferativas.

Info

Publication number
MX2009010660A
MX2009010660A MX2009010660A MX2009010660A MX2009010660A MX 2009010660 A MX2009010660 A MX 2009010660A MX 2009010660 A MX2009010660 A MX 2009010660A MX 2009010660 A MX2009010660 A MX 2009010660A MX 2009010660 A MX2009010660 A MX 2009010660A
Authority
MX
Mexico
Prior art keywords
alkyl
haloalkyl
purine derivatives
compounds
independently
Prior art date
Application number
MX2009010660A
Other languages
English (en)
Inventor
Simon Green
Peter William Sheldrake
Butrus Atrash
Edward Mcdonald
Sheelagh Frame
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of MX2009010660A publication Critical patent/MX2009010660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) en donde R1 y R2 son cada una independientemente H, alquilo o haloalquilo; R3 y R4 son cada uno independientemente H, alquilo, haloalquilo o arilo; R5 es alquilo, cicloalquilo o cicloalquil-alquilo, cada uno de los cuales puede ser substituido opcionalmente por uno o más grupos OH; R6 es seleccionado de ciclopropilamino, ciclopropilmetilamino, ciclobutilamino, ciclobutilmetilamino y la fórmula (a) en donde uno de X,Y y Z es N y el resto son CR9 R7, R8 y cada R9 son independientemente H, alquilo o haloalquilo, en donde por lo menos uno de R7, R8 y cada R9 son diferentes a H. En un aspecto adicional de la presente invención, se refiere a composiciones farmacéuticas que comprenden los compuestos de la fórmula (I), y el uso de dichos compuestos en el tratamiento de enfermedades proliferativas, enfermedades virales, ataques, alopecía, enfermedad del sistema nervioso central (CNS), enfermedades neurodegenerativas o diabetes.
MX2009010660A 2007-04-04 2008-04-02 Derivados de purina substituidos-2,6,9 que tienen propiedades anti-proliferativas. MX2009010660A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92189707P 2007-04-04 2007-04-04
GBGB0706632.7A GB0706632D0 (en) 2007-04-04 2007-04-04 New purine derivatives
PCT/GB2008/001173 WO2008122767A2 (en) 2007-04-04 2008-04-02 2, 6, 9-substituted purine derivatives having anti proliferative properties

Publications (1)

Publication Number Publication Date
MX2009010660A true MX2009010660A (es) 2010-02-17

Family

ID=38090893

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010660A MX2009010660A (es) 2007-04-04 2008-04-02 Derivados de purina substituidos-2,6,9 que tienen propiedades anti-proliferativas.

Country Status (14)

Country Link
US (1) US8592581B2 (es)
EP (1) EP2139893B1 (es)
JP (1) JP5466145B2 (es)
CN (1) CN101679434B (es)
AU (1) AU2008235361B2 (es)
BR (1) BRPI0809996B8 (es)
CA (1) CA2681529C (es)
ES (1) ES2427845T3 (es)
GB (1) GB0706632D0 (es)
HK (1) HK1139939A1 (es)
MX (1) MX2009010660A (es)
PL (1) PL2139893T3 (es)
RU (1) RU2461559C2 (es)
WO (1) WO2008122767A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0903346D0 (en) 2009-02-27 2009-04-08 Cambridge Advanced Tech Transgenic Plants
GB201001075D0 (en) * 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
DK3244891T3 (da) 2015-01-16 2022-10-24 Massachusetts Gen Hospital Forbindelser til forbedring af mrna-splejsning
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
US10927113B2 (en) 2017-01-26 2021-02-23 Cyclacel Limited Process for preparing purine derivatives
EP3388432A1 (en) 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
RU2754441C2 (ru) * 2019-12-30 2021-09-02 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
GB202000901D0 (en) 2020-01-22 2020-03-04 Cyclacel Ltd Process
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
RU2001124352A (ru) * 1999-02-01 2004-02-20 Си Ви Терапьютикс, Инк. (Us) Пуриновые ингибиторы циклин-зависимой киназы 2 и Ikb-альфа
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
WO2003002565A1 (en) * 2001-06-27 2003-01-09 Cyclacel Limited 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
ATE433967T1 (de) * 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
MX2007002169A (es) * 2004-08-27 2007-08-14 Cyclacel Ltd Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes.
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination

Also Published As

Publication number Publication date
WO2008122767A3 (en) 2008-12-31
JP2010523534A (ja) 2010-07-15
US8592581B2 (en) 2013-11-26
AU2008235361A1 (en) 2008-10-16
HK1139939A1 (en) 2010-09-30
RU2009140753A (ru) 2011-05-10
BRPI0809996B1 (pt) 2019-09-03
JP5466145B2 (ja) 2014-04-09
CA2681529C (en) 2015-06-30
WO2008122767A2 (en) 2008-10-16
CN101679434B (zh) 2013-09-25
ES2427845T3 (es) 2013-11-04
BRPI0809996B8 (pt) 2021-05-25
BRPI0809996A2 (pt) 2014-10-14
EP2139893B1 (en) 2013-06-19
AU2008235361B2 (en) 2013-02-14
RU2461559C2 (ru) 2012-09-20
US20100093769A1 (en) 2010-04-15
GB0706632D0 (en) 2007-05-16
PL2139893T3 (pl) 2013-11-29
EP2139893A2 (en) 2010-01-06
CN101679434A (zh) 2010-03-24
CA2681529A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
MX2009010660A (es) Derivados de purina substituidos-2,6,9 que tienen propiedades anti-proliferativas.
TW200740773A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
AR065276A1 (es) Herbicidas de n-oxidos de piridina sustituidos
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
TW200628154A (en) Organic compounds
ATE523514T1 (de) Tricyclische triazolische verbindungen
NO20090760L (no) Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet
DOP2007000051A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
MX2009005185A (es) Analogos de tiofeno para el tratamiento o prevencion de infecciones de flavivirus.
ES2531324T3 (es) Intermedio para producir un derivado de gamma-aminoácido bicíclico
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
NO20055688L (no) Organiske forbindelser
JO2910B1 (en) Organic compounds
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
TW200745056A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
BR112012007411A2 (pt) composto, processo para sua preparação e composição farmacêutica contendo o mesmo
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
BRPI0519292A2 (pt) compostos orgÂnicos
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
GB0513886D0 (en) Novel compounds

Legal Events

Date Code Title Description
FG Grant or registration